Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - selexipag - film-coated tablet - 1400 µg,

Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - selexipag - film-coated tablet - 1600 µg,

Arabia Saudita - inglese - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - selexipag - film-coated tablet - 800 µg,

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1000ug - film coated tablet - 1000 mcg - active: selexipag 1000ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide red iron oxide yellow magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1200ug - film coated tablet - 1200 mcg - active: selexipag 1200ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide black iron oxide red magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1400ug - film coated tablet - 1400 mcg - active: selexipag 1400ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide yellow magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 1600ug - film coated tablet - 1600 mcg - active: selexipag 1600ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide black iron oxide red iron oxide yellow magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 200ug - film coated tablet - 200 mcg - active: selexipag 200ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide yellow magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 400ug - film coated tablet - 400 mcg - active: selexipag 400ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide red magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.

Nuova Zelanda - inglese - Medsafe (Medicines Safety Authority)

janssen-cilag (new zealand) ltd - selexipag 600ug - film coated tablet - 600 mcg - active: selexipag 600ug excipient: carnauba wax hyprolose hypromellose disintergrant/low substituted hydroxypropyl cellulose iron oxide black iron oxide red magnesium stearate maize starch mannitol propylene glycol titanium dioxide - uptravi, is indicated for the treatment of: · idiopathic pulmonary arterial hypertension · heritable pulmonary arterial hypertension · pulmonary arterial hypertension associated with connective tissue disease · pulmonary arterial hypertension associated with congenital heart disease with repaired shunts · pulmonary arterial hypertension associated with drugs and toxins in patients with who functional class ii, iii or iv symptoms. uptravi is effective in combination with an endothelin receptor antagonist (era) or a phosphodiesterase-5 (pde-5) inhibitor, or in triple combination with an era and a pde-5 inhibitor, or as monotherapy.